TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27339864

Group type: EXPERIMENTAL
Intervention: Transfusion of parasitemic whole blood (WB) units
Number of subjects: 37
Study: 25708531

Group type: EXPERIMENTAL
Intervention: Cal/BD foam
Number of subjects: 24

Group type: COMPARATOR
Intervention: Cal/BD ointment
Number of subjects: 24

Group type: COMPARATOR
Intervention: BD foam
Number of subjects: 24

Group type: COMPARATOR
Intervention: Foam vehicle
Number of subjects: 24
Study: 24088075

Group type: EXPERIMENTAL
Intervention: V7 (10 µg heat-killed Mycobacterium vaccae)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 21045188

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 13
Study: 18718871

Group type: EXPERIMENTAL
Intervention: Amino acid mixture designed to deplete plasma tryptophan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16054286

Group type: EXPERIMENTAL
Intervention: Induction of labour
Number of subjects: 33

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 33
Study: 14514588

Group type: EXPERIMENTAL
Intervention: GLP-1 (120 pmol x kg(‐1). h(‐1) for 12 weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Usual glucose-lowering therapy
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: GLP-1
Number of subjects: 16
Study: 10908083

Group type: EXPERIMENTAL
Intervention: Felodipine extended release (ER)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study: 8969731

Group type: EXPERIMENTAL
Intervention: Pause in rhGH therapy (group 1) for a mean duration of 25.5 +/- 26.9 months.
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Resumption of rhGH therapy after a pause (group 2) for a mean duration of 9.0 +/- 4.6 months.
Number of subjects: 52

Group type: COMPARATOR
Intervention: Discontinuation of rhGH therapy at the time of transplantation (30 patients).
Number of subjects: 52

Group type: COMPARATOR
Intervention: Post-transplantation growth velocity after discontinuation of rhGH therapy.
Number of subjects: 52

Group type: COMPARATOR
Intervention: Delta height SDS at last follow-up after discontinuation of rhGH therapy.
Number of subjects: 52
Study: 1471603

Group type: EXPERIMENTAL
Intervention: Beta-receptor antagonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thiazide diuretics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calcium antagonists
Number of subjects: 0

Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 0
Study: 6327758

Group type: EXPERIMENTAL
Intervention: RU 486 (400 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RU 486 (200 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: RU 486 (400 mg) at 1400 h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RU 486 (400 mg) with dexamethasone (1 mg) at 2400 h
Number of subjects: 0
Study: 28820651

Group type: EXPERIMENTAL
Intervention: Rear mounted powered drive wheel
Number of subjects: 24
Study: 29216922

Group type: EXPERIMENTAL
Intervention: Lactic-fermented egg white (LE)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (whey)
Number of subjects: 37
Study: 25417935

Group type: EXPERIMENTAL
Intervention: Psychoeducative group intervention with relaxation (n=131; six sessions during pregnancy, one postnatal)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Psychoeducative group intervention with relaxation (n=131)
Number of subjects: 371

Group type: COMPARATOR
Intervention: Conventional care (n=240)
Number of subjects: 371
Study: 24350806

Group type: EXPERIMENTAL
Intervention: Home telemonitoring of blood glucose and blood pressure
Number of subjects: 108
Study: 21981375

Group type: EXPERIMENTAL
Intervention: CS20 protective barrier gel
Number of subjects: 106

Group type: COMPARATOR
Intervention: Topical aciclovir
Number of subjects: 106
Study: 19030969

Group type: EXPERIMENTAL
Intervention: Early Gp IIb‐IIIa inhibitors
Number of subjects: 1662
Study: 17726080

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate, high-fat (LCHF) diet
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low-fat, high-carbohydrate (LFHC) diet
Number of subjects: 18
Study: 15224023

Group type: EXPERIMENTAL
Intervention: Cold blood cardioplegia with a hot shot
Number of subjects: 103

Group type: COMPARATOR
Intervention: Cold crystalloid cardioplegia
Number of subjects: 103

Group type: COMPARATOR
Intervention: Cold blood cardioplegia
Number of subjects: 103
Study: 15922817

Group type: EXPERIMENTAL
Intervention: Amlodipine maleate
Number of subjects: 118

Group type: COMPARATOR
Intervention: Amlodipine besylate
Number of subjects: 118
Study: 10484301

Group type: EXPERIMENTAL
Intervention: Lap-Band operation
Number of subjects: 39
Study: 8767776

Group type: EXPERIMENTAL
Intervention: Diltiazem SR (120 mgs bid)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 1909273

Group type: EXPERIMENTAL
Intervention: Interferon treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (untreated patients)
Number of subjects: 28
Study: 6759647

Group type: EXPERIMENTAL
Intervention: Chlormezanone
Number of subjects: 10
Study: 31376908

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (15 mg daily)
Number of subjects: 3250

Group type: COMPARATOR
Intervention: Standard of care (placebo or acetylsalicylic acid 100 mg daily)
Number of subjects: 3250
Study: 29414618

Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia (SA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 40
Study: 27121793

Group type: EXPERIMENTAL
Intervention: Capecitabine plus irinotecan (CAPIRI) therapy
Number of subjects: 183

Group type: COMPARATOR
Intervention: Capecitabine monotherapy
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Not applicable (general finding)
Number of subjects: 183
Study: 24717890

Group type: EXPERIMENTAL
Intervention: Spreader flap technique
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (no spreader flap)
Number of subjects: 66
Study: 21607554

Group type: EXPERIMENTAL
Intervention: Docetaxel-based doublet
Number of subjects: 2126

Group type: COMPARATOR
Intervention: Single-agent docetaxel
Number of subjects: 2126
Study: 20716839

Group type: EXPERIMENTAL
Intervention: Tai Chi training (supervised once a week and home-based three times a week for one year)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional cardiac rehabilitation only
Number of subjects: 20
Study: 18341819

Group type: EXPERIMENTAL
Intervention: Positive autoantibodies against AT(1)-receptor
Number of subjects: 592

Group type: COMPARATOR
Intervention: Negative autoantibodies against AT(1)-receptor
Number of subjects: 592
Study: 16343101

Group type: COMPARATOR
Intervention: Resistance training exercise, three times/week for 1 h/session (n = 65)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Tai Chi, three times/week for 1 h/session (n = 64)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Usual level of physical activity control group (n = 78)
Number of subjects: 207
Study: 11870488

Group type: EXPERIMENTAL
Intervention: iodixanol 320 mgI/ml
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: iodixanol 270 mgI/ml
Number of subjects: 315

Group type: COMPARATOR
Intervention: iotrolan 300 mgI/ml
Number of subjects: 315
Study: 11382891

Group type: EXPERIMENTAL
Intervention: 48 hours sleep deprivation
Number of subjects: 16

Group type: COMPARATOR
Intervention: Regular sleep schedule (Control)
Number of subjects: 16
Study: 7787395

Group type: EXPERIMENTAL
Intervention: Astragalus membranaceus (AM)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 92

Group type: COMPARATOR
Intervention: Tab. Salviae miltiorrhizae
Number of subjects: 92
Study: 31876594

Group type: EXPERIMENTAL
Intervention: TAF/FTC+DTG
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: TDF/FTC+DTG
Number of subjects: 48

Group type: COMPARATOR
Intervention: TDF/FTC/EFV
Number of subjects: 48
Study: 31446510

Group type: EXPERIMENTAL
Intervention: Clinical pathway treatment (n=17)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (n=15)
Number of subjects: 32
Study: 27367794

Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (BCAA), arginine, and citrulline (0.17 g/kg BCAA, 0.05 g/kg arginine, 0.05 g/kg citrulline)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (PB trial)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (BCAA), arginine, and citrulline
Number of subjects: 9
Study: 26516908

Group type: EXPERIMENTAL
Intervention: Oligofructose-enriched inulin (5 g)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 47
Study: 23238663

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (1.8 g eicosapentaenoic acid and 1.5 g docosahexaenoic acid)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Identical olive oil capsules (placebo)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids
Number of subjects: 45
Study: 21870665

Group type: EXPERIMENTAL
Intervention: Psychogenic illness induction group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychogenic illness induction plus media group
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 0
Study: 17625310

Group type: EXPERIMENTAL
Intervention: Continuous regional arterial infusion of a protease inhibitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 16273634

Group type: EXPERIMENTAL
Intervention: TACE-PEI
Number of subjects: 52

Group type: COMPARATOR
Intervention: TACE
Number of subjects: 52
Study: 11792410

Group type: EXPERIMENTAL
Intervention: MEP regimen
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: C-MEP regimen
Number of subjects: 49
Study: 10626026

Group type: EXPERIMENTAL
Intervention: Pilot study for asbestos-exposed workers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pilot study for smokers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline predictors for asbestos-exposed participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline predictors for smoker participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reasons for inactivity
Number of subjects: 0
Study: 7485849

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 72

Group type: COMPARATOR
Intervention: No alcohol
Number of subjects: 72

Group type: COMPARATOR
Intervention: Active placebo beverage
Number of subjects: 72
Study: 1657506

Group type: EXPERIMENTAL
Intervention: 300 mg of aspirin daily in the morning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 600 mg of aspirin four times a day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin (both doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin (600 mg four times a day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enteric coating of aspirin
Number of subjects: 0
Study: 6800636

Group type: EXPERIMENTAL
Intervention: Supervoltage radiotherapy with one fractionation scheme
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supervoltage radiotherapy with another fractionation scheme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31515735

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 207

Group type: COMPARATOR
Intervention: Control
Number of subjects: 207
Study: 30882683

Group type: EXPERIMENTAL
Intervention: Single-tunnel ACL double-bundle anatomic reconstruction
Number of subjects: 58

Group type: COMPARATOR
Intervention: Double-tunnel ACL double-bundle anatomic reconstruction
Number of subjects: 58
Study: 30012822

Group type: EXPERIMENTAL
Intervention: Increased systolic blood pressure variability (BPV) during the acute period (2-24 hours postrandomization)
Number of subjects: 913

Group type: EXPERIMENTAL
Intervention: Increased systolic blood pressure variability (BPV) during the subacute period (days 2, 3, and 7)
Number of subjects: 913

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure mean
Number of subjects: 913
Study: 27418597

Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg/d without loading dose) plus Aspirin (300 mg loading followed by 100 mg/d)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Aspirin (300 mg loading followed by 100 mg/d)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus Aspirin
Number of subjects: 358

Group type: COMPARATOR
Intervention: Aspirin monotherapy
Number of subjects: 358
Study: 24556888

Group type: EXPERIMENTAL
Intervention: Theatre with floor drainage
Number of subjects: 1027

Group type: COMPARATOR
Intervention: Theatre without floor drainage
Number of subjects: 1027
Study: 23107508

Group type: EXPERIMENTAL
Intervention: 2 mg of nicotine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19767012

Group type: EXPERIMENTAL
Intervention: Pro-constancy condition (fixed biological traits)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Anti-constancy condition (mutable biological traits)
Number of subjects: 62
Study: 18386234

Group type: EXPERIMENTAL
Intervention: Midazolam 0.05 mg/kg IV (Group I)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Meperidine 0.3 mg/kg IV followed by midazolam 0.05 mg/kg IV (Group II)
Number of subjects: 30
Study: 15925264

Group type: EXPERIMENTAL
Intervention: Computer-based brief motivational intervention (motivation enhancement system, or MES)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 80
Study: 12402990

Group type: EXPERIMENTAL
Intervention: R‐wave‐triggered imaging using a 7.5‐MHz ultrasound transducer with acquisition every 41.7‐66.7 ms
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ignoring temporal position within the cardiac cycle
Number of subjects: 24
Study: 10436098

Group type: EXPERIMENTAL
Intervention: Aspirin (antiplatelet medication)
Number of subjects: 140

Group type: COMPARATOR
Intervention: No aspirin (control group)
Number of subjects: 140
Study: 7775993

Group type: EXPERIMENTAL
Intervention: Mailed feedback on prescribing profiles and treatment recommendations for insomnia and acute cystitis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (GPs in Romsdal without feedback)
Number of subjects: 0
Study: 1971855

Group type: EXPERIMENTAL
Intervention: Befunolol 0.5%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pindolol 1%
Number of subjects: 60

Group type: COMPARATOR
Intervention: NaCl 0.9% (Placebo)
Number of subjects: 60
Study: 479383

Group type: EXPERIMENTAL
Intervention: Penbutolol 25 to 75 mg twice daily (group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Penbutolol 50 to 150 mg twice daily (group B)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (control period)
Number of subjects: 30
Study: 31054396

Group type: EXPERIMENTAL
Intervention: Tree thinning treatments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control plots
Number of subjects: 0
Study: 29505422

Group type: EXPERIMENTAL
Intervention: Coping skills training program
Number of subjects: 260

Group type: COMPARATOR
Intervention: Education program
Number of subjects: 260
Study: 26714939

Group type: EXPERIMENTAL
Intervention: Ultrasonic Scalpel (USS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (ligation and monopolar electrocautery)
Number of subjects: 80
Study: 24598043

Group type: EXPERIMENTAL
Intervention: Balloon dilation of the maxillary sinuses/ethmoid infundibula with or without frontal or sphenoid ostial dilation
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Balloon dilation
Number of subjects: 81
Study: 21728184

Group type: EXPERIMENTAL
Intervention: Functioning Improvement Tool (FIT) home-visit program for 3 months, 60 minutes per visit
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control group (no home visits)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Functioning Improvement Tool (FIT) home-visit program for subjects with mild cognitive decline (baseline MMSE scores from 18 to 23 points)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control group for subjects with mild cognitive decline
Number of subjects: 199
Study: 20085915

Group type: EXPERIMENTAL
Intervention: Vitrolife culture medium
Number of subjects: 188

Group type: COMPARATOR
Intervention: Cook culture medium
Number of subjects: 188
Study: 17964399

Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine LS 0.4% (Acular)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Nepafenac 0.1% (Nevanac)
Number of subjects: 183
Study: 16098067

Group type: COMPARATOR
Intervention: CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: CIOP (cyclophosphamide, idarubicin, vincristine and prednisolone)
Number of subjects: 211

Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: CIOP
Number of subjects: 211
Study: 12190265

Group type: EXPERIMENTAL
Intervention: Laser therapy
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard surgery (transurethral resection of the prostate)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conservative management (monitoring without active intervention)
Number of subjects: 33
Study: 10909487

Group type: EXPERIMENTAL
Intervention: Acute myocardial infarction
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Acute myocardial ischemia
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Acute myocardial ischemia and acute myocardial infarction
Number of subjects: 75

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 75
Study: 7601015

Group type: EXPERIMENTAL
Intervention: Fleroxacin 200 mg or 400 mg once daily for uncomplicated urinary tract infections
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fleroxacin 200 mg or 400 mg single oral dose for gonorrhoea
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg once daily for complicated urinary tract infections
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg once daily for lower respiratory tract infections
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg once daily for skin and soft tissue infections
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg once daily for pyelonephritis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg once daily for bacterial enteritis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg once daily for typhoid fever
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg once daily for bone and joint infections (preliminary studies)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fleroxacin 200 mg/day orally or 400 mg/day orally or intravenously
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fleroxacin 400 mg once daily compared to ofloxacin 800 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fleroxacin 400 mg once daily compared to ciprofloxacin 1000 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fleroxacin 200 mg once daily compared to norfloxacin 800 mg/day
Number of subjects: 0
Study: 2253290

Group type: EXPERIMENTAL
Intervention: Mepivacaine 1.5% (0.35 ml.kg‐1) + norepinephrine (5 micrograms.ml‐1)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% + norepinephrine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Bupivacaine 0.25%
Number of subjects: 22
Study: 7343850

Group type: EXPERIMENTAL
Intervention: Surgical technique group I (64 cases): craniectomy with open dura mater fixed to lateral musculature
Number of subjects: 126

Group type: COMPARATOR
Intervention: Surgical technique group II (62 cases): endotracheal intubation without head flexion, plastic closure of the dura
Number of subjects: 126
Study: 31968063

Group type: EXPERIMENTAL
Intervention: Prehabilitation (Prehab) group
Number of subjects: 110

Group type: COMPARATOR
Intervention: Rehabilitation (Rehab) group
Number of subjects: 110
Study: 29361297

Group type: EXPERIMENTAL
Intervention: Rest then Exercise
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 18

Group type: COMPARATOR
Intervention: Not having surgery
Number of subjects: 18
Study: 27595693

Group type: EXPERIMENTAL
Intervention: Insulin Degludec (IDeg)
Number of subjects: 7637

Group type: COMPARATOR
Intervention: Insulin Glargine U100 (IGlar)
Number of subjects: 7637

Group type: EXPERIMENTAL
Intervention: Composite outcome (IDeg and IGlar)
Number of subjects: 7637
Study: 25044079

Group type: EXPERIMENTAL
Intervention: Culture at 37°C
Number of subjects: 52

Group type: COMPARATOR
Intervention: Culture at 36°C
Number of subjects: 52
Study: 22948779

Group type: EXPERIMENTAL
Intervention: Activated carbon nanoparticle-epirubicin suspension
Number of subjects: 120

Group type: COMPARATOR
Intervention: Epirubicin control group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 120
Study: 20859315

Group type: EXPERIMENTAL
Intervention: Topical ibuprofen (4% gel, 320 mg total, 4 times daily for 2 weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen (2400 mg total, 3 times daily for 2 weeks)
Number of subjects: 20
Study: 18420964

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (22 g/d loading for 5 days; maintenance 3.76 g/d during PR)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 100
Study: 15871870

Group type: EXPERIMENTAL
Intervention: Radiant-heat dressing device
Number of subjects: 41

Group type: COMPARATOR
Intervention: Hydrocolloid dressing (with or without calcium alginate filler)
Number of subjects: 41
Study: 12651678

Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5% with epinephrine 1:200,000 (3 mL)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Epidural saline (3 mL)
Number of subjects: 153
Study: 11200792

Group type: EXPERIMENTAL
Intervention: Oral lysine acetylsalicylate (1620 mg) combined with metoclopramide (10 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral sumatriptan (100 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8804681

Group type: EXPERIMENTAL
Intervention: Nicotine (20 micrograms/kg per dosing)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nicotine combined with alcohol (0.5 g/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Alcohol alone (0.5 g/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nicotine alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nicotine and alcohol combined
Number of subjects: 18